000			01604nam a2200121Ia 4500
008			220616s9999||||xx |||||||||||||| ||und||
245		0	_aRheumatoid Arthritis Therapy Reappraisal _bStrategies, Opportunities and Challenges
546			_aEnglish[eng]
650			_arheumatoid arthritis||sleep||sleep disorders||pain||osteoporosis||fracture||fracture risk assessment tool||treat-to-target||certolizumab pegol||csDMARDs||glucocorticoids||intra-articular injections||DAS 28||ACR response||HAQ-DI||TNFα||golimumab||efficacy||tolerability||immunogenicity||methotrexate||posology||titration||oral route||subcutaneous route||bioavailability||effectiveness||periodontitis||periodontal disease||anti-citrullinated protein autoantibodies||rheumatoid factor||smoking||medication||Porphyromonas gingivalis||Rheumatoid arthritis||matrix metalloproteinase 3||infliximab||pharmacogenomics||anti-TNF||personalized medicine||baricitinib||disease-modifying antirheumatic drugs||pain perception||outcomes research||patient perspective||Rheumatoid Arthritis||therapy||DMARD||MTX||Tumor Necrosis Factor-Alpha Inhibitors||ankylosing spondylitis||biosimilar||switching||synovial fibroblasts||cytokine||osteoclast||herbal medicine||methylation||next-generation sequencing||recovery of function||fatigue||productivity||tofacitinib||oral||Th1.17||IL-17A||IFN-γ, CD73||adenosine||psoriatic arthritis||regulation||pseudoerosions||hand||foot||ultrasonography||radiography||computed tomography||magnetic resonance imaging||n/a
700			_aMüller, Rüdiger
856			_uhttps://mdpi.com/books/pdfview/book/2866
942			_cEB
999			_c19557 _d19557